Key Takeaways:
- AATec Medical, a German biotech startup, secures EUR 2.7 million in seed funding to further their work in alpha-1 antitrypsin (AAT).
- The company is developing a novel formulation of AAT for respiratory applications, with clinical trials expected to start in 2024.
- AATec’s focus lies in the treatment of inflammatory airway conditions and respiratory virus infections.
AATec Medical Kickstarts Operations with Promising Seed Funding
Munich-based biotech firm, AATec Medical GmbH (AATec), commences operations backed by seed financing worth EUR 2.7 million. The capital injection, sourced from private investors, industry experts, and family offices, will be used to scale AATec’s technology, broaden their team, and prepare for the launch of clinical studies expected to start in the first half of 2024.
AATec is dedicated to the development of a multi-product platform grounded on the recombinant alpha-1 antitrypsin (AAT), a human serine protease inhibitor that exhibits promising immunomodulatory functions with anti-inflammatory and antiviral effects. The initial product under development, ATL-105, is a ground-breaking AAT formulation designed for inhalation, targeting the treatment of emerging inflammatory diseases of the lung and respiratory virus infections.
The Potential of Alpha-1 Antitrypsin (AAT)
Currently, commercially available AAT products, produced exclusively from human plasma, are utilized for treating AAT deficiency, a severe genetic disorder. However, these resources are both scarce and expensive.
To overcome these challenges, AATec has successfully developed a high-yield industrial manufacturing process for recombinant AAT. In multiple preclinical models for inflammatory lung conditions and respiratory virus infections, the therapeutic concept has been validated. Backed by a portfolio of patents, the company’s technology stems from extensive research by co-founders Dr. Manfred Stangl and Dr. Michael Strassmair, both highly experienced sector specialists.
Promising Prospects for Future Treatment
AATec’s initial efforts will focus on the development of novel therapies for inflammatory conditions in the respiratory system, including acute respiratory distress syndrome (ARDS), respiratory virus infections, and allergic asthma. Long-term R&D strategies plan to extend these treatments to conditions such as transplant complications, AAT deficiency, and systemic inflammatory diseases.
CEO Dr. Rüdiger Jankowsky shared his excitement about AAT’s therapeutic potential, expressing confidence in the combination of AAT with innovative inhalation technology to “make a decisive difference in the future treatment of inflammatory and infectious diseases.”
Dr. Karsten Ottenberg, co-founder and chairman of AATec, reflected on the potential societal impact of AAT in addressing unmet medical needs in a range of severe diseases, including current endemic and potential future pandemic challenges from viral diseases.
About AATec
Founded by a seasoned interdisciplinary team, AATec Medical GmbH is a biotechnology company specializing in the development of a product platform based on recombinant alpha-1 antitrypsin (AAT). The company’s mission is to revolutionize the treatment landscape for inflammatory diseases, virus infections, and rare diseases. With several successful demonstrations of proof-of-principle for several indications, AATec is currently preparing for a proof-of-concept clinical trial with their first product candidate, ATL-105, targeting respiratory diseases.
Sign up to our newsletter & get the most important monthly insights from around the world.
Ready to Amplify Your Brand with Business Today?
Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!
Click here to explore our Promotion & Sponsored Articles page.
Are you looking to make an impact? Contact us at [email protected] to get started!
